Mesoblast

Mesoblast Employees

The The number of employees of Mesoblast (MSB.AX) as of Nov 2, 2026 is 83. In the previous year, The number of employees was 83.00 — a change of 0.00% (lower).

Employees

83

YoY

0.00%

Last updated:

In 2026, Mesoblast employed 83 people, a 0.00% change from the 83.00 number of employees in the previous year.

The Mesoblast Employees history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Employees
Date
Employees
Jan 1, 2019
83.00 USD
Jan 1, 2020
83.00 USD
Jan 1, 2021
83.00 USD
Jan 1, 2022
83.00 USD
Jan 1, 2023
83.00 USD
Jan 1, 2024
83.00 USD
Jan 1, 2025
83.00 USD
Jan 1, 2026
83.00 USD
The Mesoblast Employees history
YEAREmployeesYoY
830.00%
830.00%
830.00%
830.00%
830.00%
830.00%
830.00%
830.00%
830.00%
830.00%
830.00%
830.00%
83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Employees Details

Examining Mesoblast's Employee Base

Mesoblast's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Mesoblast's operational capacity and future potential.

Year-to-Year Comparison

Assessing Mesoblast's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Mesoblast's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Mesoblast’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Mesoblast stock

The number of employees of Mesoblast is 83 in 2026.

The number of employees of Mesoblast changed from 83.00 to 83, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of employees Mesoblast since 2006 – with annual values, charts, and detailed analysis.

The number of employees describes the number of people directly employed by the company.

The number of employees's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The number of employees's Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Mesoblast

All Key Metrics — Mesoblast